IP Library Granted Patent US 10,576,165
Granted Patent B2
US 10,576,165 · App. 16/157,343 · Granted Mar 3, 2020

ST-246 liquid formulations and methods

Inventors: Shanthakumar R. Tyavanagimatt (Corvallis, OR); Melialani A. C. L. S. Anderson (Corvallis, OR); William Weimers (Corvallis, OR); Gopi Krishna Kasi (Lynnwood, WA); N K Peter Samuel (Corvallis, OR); Tove C. Bolken (Keizer, OR); Dennis E. Hruby (Albany, OR)
Assignee: Siga Technologies Inc.
A61K47/6951A61K9/0014A61K9/0019A61K9/08A61K31/4035A61K31/715A61K31/724A61K47/10A61K47/26A61K47/40C12N2710/24071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,165
App. No.
16/157,343
Granted
Mar 3, 2020
Kind
B2
Abstract

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

Claims (13)

1. A unit dosage liquid formulation comprising:

a) ST-246 content ranging from about 2 mg/ml to about 20 mg/ml; and

b) hydroxypropyl-β-cyclodextrin content ranging from about 125 mg/ml to about 400 mg/ml.

2. The unit dosage liquid formulation of claim 1 further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of: mannitol, trehalose dehydrate, lactose monohydrate, and purified water.

3. The unit dosage liquid formulation of claim 1 having a pH range from about 3.0 to about 10.0.

4. The unit dosage liquid formulation of claim 1 having a total volume of about 100 ml.

5. A unit dosage liquid formulation comprising:

a) ST-246 ranging from about 2 mg/ml to about 20 mg/ml; and

hydroxypropyl-β-cyclodextrin content ranging from about 12.5 mg/ml to about 40 mg/ml.

6. The unit dosage liquid formulation of claim 5 further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of:

polyethylene glycol 400, polysorbate 80, polyethylene glycol 300, and purified water.

7. The unit dosage liquid formulation of claim 5 having a total volume of about 100 ml.

8. The unit dosage liquid formulation of claim 5 having a pH range from about 3.0 to about 10.0.

Assignments (2)
CHANGE OF ADDRESS Recorded Mar 25, 2026
From: SIGA TECHNOLOGIES, INC.
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 075242/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: TYAVANAGIMATT, SHANTHAKUMAR R.; ANDERSON, MELIALANI A.C.L.S.; WEIMERS, WILLIAM; KASI, GOPI KRISHNA; SAMUEL, N K PETER; BOLKEN, TOVE C.; HRUBY, DENNIS E.
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 047132/0816 →
Continuity (6)
Division 15872505 · Jan 16, 2018
Division 14955674 · Dec 1, 2015
Division 13814102
Provisional Application 61370971 · Aug 5, 2010
Provisional Application 61450359 · Mar 8, 2011
Related Publication 20190038767A1 · Feb 7, 2019